Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Antiviral Res. 2012 Oct 6;96(3):363–375. doi: 10.1016/j.antiviral.2012.09.020

FIGURE 3. Neutralization, prophylaxis, or therapeutic treatment with ZnOT inhibits HSV-2 entry.

FIGURE 3

A β-galactosidase-expressing reporter virus, HSV-2(333)gJ-was used for entry measurements. Viral entry was determined after each of the treatments indicated. UV treated (UV) or non-UV treated (NUV) ZnOTs were tested. (A) Neutralization. ZnOT was allowed to bind the virus and the virus/ZnOT mixture was then used to infect cells. (B) Prophylaxis treatment. Cells were pretreated with ZnOTs and then infected with HSV-2(333)gJ- virus. (C) Therapeutic treatment. Cells were first infected with HSV-2(333)gJ- and then treated with the ZnOTs.